Genfit (GNFT.PA)

Executive Summary

Genfit is a French biopharmaceutical company dedicated to developing novel therapies and diagnostics for metabolic and liver diseases, with a strong focus on nuclear receptor biology. The company's late-stage pipeline includes elafibranor, a PPARα/δ agonist previously investigated for NASH, and GNS561, a lysosomotropic compound in Phase 1/2 for cholangiocarcinoma. Genfit also commercializes NIS4, a non-invasive diagnostic for NASH. Despite the termination of elafibranor's Phase 3 NASH trial and the VS-01 acute-on-chronic liver failure study, the company continues to advance GNS561, which is currently recruiting for a Phase 1/2 trial with expected completion in Q4 2026. With a market cap of approximately €400 million, Genfit represents a speculative investment hinging on the success of its pipeline and potential strategic partnerships.

Upcoming Catalysts (preview)

• Q4 2026Phase 1/2 data readout for GNS561 + Trametinib in cholangiocarcinoma40% success
• H2 2026Potential partnership or licensing deal for NIS4 or elafibranor30% success
• H2 2026Regulatory update on NIS4 diagnostic approval in Europe50% success